Published in J Clin Oncol on July 01, 2001
Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol (2010) 3.80
Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat Rev Drug Discov (2009) 3.64
Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells. Cancer Immunol Immunother (2009) 2.25
MET: a promising anticancer therapeutic target. Nat Rev Clin Oncol (2012) 1.71
The combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancer. Clin Cancer Res (2008) 1.68
Targeting ALK in neuroblastoma--preclinical and clinical advancements. Nat Rev Clin Oncol (2012) 1.42
Combination chemotherapy and radiation of human squamous cell carcinoma of the head and neck augments CTL-mediated lysis. Clin Cancer Res (2006) 1.36
Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. Cancer Biol Ther (2011) 1.31
Molecular therapy in head and neck oncology. Nat Rev Clin Oncol (2009) 1.24
Recent advances in anti-angiogenic therapy of cancer. Oncotarget (2011) 1.22
Targeting the epidermal growth factor receptor. Br J Cancer (2004) 1.14
Targeting EGF-receptor-signalling in squamous cell carcinomas of the head and neck. Br J Cancer (2007) 1.14
Functional dissection of the epidermal growth factor receptor epitopes targeted by panitumumab and cetuximab. Neoplasia (2012) 1.07
The role of cetuximab for the treatment of squamous cell carcinoma of the head and neck. Clin Adv Hematol Oncol (2008) 1.06
Immunotherapy of cancer. Eur J Pharmacol (2009) 1.05
Interaction of radiation therapy with molecular targeted agents. J Clin Oncol (2014) 1.05
Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma. Oncogene (2012) 1.01
Cetuximab: its unique place in head and neck cancer treatment. Biologics (2013) 1.01
Investigational EGFR-targeted therapy in head and neck squamous cell carcinoma. Expert Opin Investig Drugs (2010) 0.99
Prognostic significance of EGFR and Her-2 in oral cavity cancer in betel quid prevalent area cancer prognosis. Br J Cancer (2003) 0.98
Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive review. J Exp Clin Cancer Res (2009) 0.97
A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall cell lung cancer. Cancer (2009) 0.96
Current trends in initial management of oropharyngeal cancer: the declining use of open surgery. Eur Arch Otorhinolaryngol (2009) 0.96
Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. Br J Cancer (2004) 0.96
Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol (2011) 0.94
A phase I clinical study of VB4-845: weekly intratumoral administration of an anti-EpCAM recombinant fusion protein in patients with squamous cell carcinoma of the head and neck. Drug Des Devel Ther (2009) 0.93
TLR3 agonists improve the immunostimulatory potential of cetuximab against EGFR(+) head and neck cancer cells. Oncoimmunology (2013) 0.92
Antibody and lectin target podoplanin to inhibit oral squamous carcinoma cell migration and viability by distinct mechanisms. Oncotarget (2015) 0.92
Anti-EMMPRIN antibody treatment of head and neck squamous cell carcinoma in an ex-vivo model. Anticancer Drugs (2010) 0.91
The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer. Biologics (2010) 0.91
Combination of radiotherapy with EGFR antagonists for head and neck carcinoma. Int J Clin Oncol (2007) 0.91
Clinical Significance of Skin Toxicity due to EGFR-Targeted Therapies. J Oncol (2009) 0.91
A phase I study evaluating the role of the anti-epidermal growth factor receptor (EGFR) antibody cetuximab as a radiosensitizer with chemoradiation for locally advanced pancreatic cancer. Cancer Chemother Pharmacol (2010) 0.91
Pharmacogenomics of chemotherapeutic susceptibility and toxicity. Genome Med (2012) 0.89
Review of cetuximab in the treatment of squamous cell carcinoma of the head and neck. Ther Clin Risk Manag (2007) 0.89
Lessons learned from radiation oncology clinical trials. Clin Cancer Res (2013) 0.89
Relevance of MET activation and genetic alterations of KRAS and E-cadherin for cetuximab sensitivity of gastric cancer cell lines. J Cancer Res Clin Oncol (2012) 0.88
Additive interaction of gefitinib ('Iressa', ZD1839) and ionising radiation in human tumour cells in vitro. Br J Cancer (2004) 0.88
Control of oncogenesis and cancer therapy resistance. Br J Cancer (2004) 0.88
Mucosal injury from targeted anti-cancer therapy. Support Care Cancer (2006) 0.88
pEGFR-Tyr 845 expression as prognostic factors in oral squamous cell carcinoma: a tissue-microarray study with clinic-pathological correlations. Cancer Biol Ther (2012) 0.87
Integrating radiotherapy with epidermal growth factor receptor antagonists and other molecular therapeutics for the treatment of head and neck cancer. Int J Radiat Oncol Biol Phys (2007) 0.86
Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group study. Gynecol Oncol (2011) 0.85
Expanding the therapeutic repertoire of epidermal growth factor receptor blockade: radiosensitization. Breast Cancer Res (2003) 0.84
Current aspects of targeted therapy in head and neck tumors. Eur Arch Otorhinolaryngol (2008) 0.84
Refractory lympho-epithelial carcinoma of the nasopharynx: a case report illustrating a protracted clinical course. Head Neck Oncol (2009) 0.83
Survival, recurrence and toxicity of HNSCC in comparison of a radiotherapy combination with cisplatin versus cetuximab: a meta-analysis. BMC Cancer (2016) 0.83
A phase I study of cetuximab in combination with gemcitabine and radiation for locally advanced pancreatic cancer. Gastrointest Cancer Res (2012) 0.82
Epidermal growth factor receptor-targeted radioimmunotherapy of human head and neck cancer xenografts using 90Y-labeled fully human antibody panitumumab. Mol Cancer Ther (2010) 0.82
Personalized Combined Modality Therapy for Locally Advanced Non-small Cell Lung Cancer. Cancer Res Treat (2012) 0.82
Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence. ESMO Open (2016) 0.81
Practical considerations for nonclinical safety evaluation of therapeutic monoclonal antibodies. MAbs (2010) 0.81
Antiepidermal growth factor receptor therapy in squamous cell carcinoma of the head and neck. J Oncol (2012) 0.81
BRET Biosensor Analysis of Receptor Tyrosine Kinase Functionality. Front Endocrinol (Lausanne) (2013) 0.81
Personalizing colon cancer therapeutics: targeting old and new mechanisms of action. Pharmaceuticals (Basel) (2013) 0.81
Targeted Therapy in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (LA-R/M HNSCC). Cancers (Basel) (2016) 0.81
Treatment of non-small cell lung cancer with intensity-modulated radiation therapy in combination with cetuximab: the NEAR protocol (NCT00115518). BMC Cancer (2006) 0.80
Recent results of cetuximab use in the treatment of squamous cell carcinoma of the head and neck. Onco Targets Ther (2009) 0.80
The role of EGFR-targeting strategies in the treatment of head and neck cancer. Onco Targets Ther (2012) 0.79
Therapeutic monoclonal antibodies in oncology. J R Soc Med (2005) 0.79
miR-143 or miR-145 overexpression increases cetuximab-mediated antibody-dependent cellular cytotoxicity in human colon cancer cells. Oncotarget (2016) 0.79
Electrolyte and protein imbalance following anti-EGFR therapy in cancer patients: A comparative study. Exp Ther Med (2010) 0.79
EGFR targeted therapies and radiation: Optimizing efficacy by appropriate drug scheduling and patient selection. Pharmacol Ther (2015) 0.79
Long-term surgical complications in the oral cancer patient: a comprehensive review. Part I. J Oral Maxillofac Res (2010) 0.78
[Evaluation of her-2/neu amplification/overexpression in OSCC with fluorescence in situ hybridization (FISH) and immunohistochemistry]. Mund Kiefer Gesichtschir (2003) 0.77
The use of epidermal growth factor receptor monoclonal antibodies in squamous cell carcinoma of the head and neck. Chemother Res Pract (2012) 0.77
Cetuximab in the treatment of head and neck cancer: preliminary results outside clinical trials. Cancer Manag Res (2010) 0.77
Cetuximab concomitant with second-line radiation therapy in patients with locally advanced recurrent squamous cell head and neck cancer. Case Rep Oncol (2010) 0.76
Rational use of cetuximab in the treatment of advanced non-small cell lung cancer. Onco Targets Ther (2009) 0.75
Effect of antigen-dependent clearance on pharmacokinetics of anti-heparin-binding EGF-like growth factor (HB-EGF) monoclonal antibody. MAbs (2014) 0.75
A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys (2000) 7.50
Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas. Polyp Prevention Trial Study Group. N Engl J Med (2000) 6.53
Red cells coated with immunoglobulin G: binding and sphering by mononuclear cells in man. Science (1967) 6.42
Human tumor necrosis factor. Production, purification, and characterization. J Biol Chem (1985) 6.28
Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med (1992) 5.42
The effect of increased salt intake on blood pressure of chimpanzees. Nat Med (1995) 4.93
Growth hormone receptor and serum binding protein: purification, cloning and expression. Nature (1988) 4.40
Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med (1994) 3.54
Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature (1994) 3.13
Role of hydrogen peroxide in neutrophil-mediated destruction of cultured endothelial cells. J Clin Invest (1981) 2.97
Continuous negative extrathoracic pressure in neonatal respiratory failure. Pediatrics (1996) 2.75
Canine Lyme disease in Belgium. Vet Rec (1995) 2.57
Human granulocyte generation of hydroxyl radical. J Exp Med (1978) 2.54
Phagocyte-generated oxygen metabolites and cellular injury. Lab Invest (1982) 2.43
Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol (1999) 2.36
A modified procedure for the determination of leukocyte alkaline phosphatase. Biochem Med (1970) 2.35
Direct determination of the protonation states of aspartic acid-102 and histidine-57 in the tetrahedral intermediate of the serine proteases: neutron structure of trypsin. Biochemistry (1981) 2.30
Characterization of glass adherent human mononuclear cells. J Immunol (1973) 2.22
Human blood monocytes: stimulators of granulocyte and mononuclear colony formation in vitro. Science (1972) 2.21
Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients. Ann Oncol (2006) 2.18
Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc Natl Acad Sci U S A (1989) 2.15
Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol (2000) 2.13
Combined neck dissection and postoperative radiation therapy in the management of the high-risk neck: a matched-pair analysis. Int J Radiat Oncol Biol Phys (1998) 2.09
Localization of iodine-125-mIP-Des-Met14-bombesin (7-13)NH2 in ovarian carcinoma induced to express the gastrin releasing peptide receptor by adenoviral vector-mediated gene transfer. J Nucl Med (1997) 2.05
Written informed consent in patients with breast cancer. Cancer (1979) 2.01
Fat content of expressed breast milk: a case for quality control. Br Med J (Clin Res Ed) (1981) 1.97
Effects of corticosteroid therapy on human monocyte function. N Engl J Med (1975) 1.96
Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association. N Engl J Med (1991) 1.89
Evidence for hydroxyl radical generation by human Monocytes. J Clin Invest (1977) 1.85
Complete deficiency of leukocyte glucose-6-phosphate dehydrogenase with defective bactericidal activity. J Clin Invest (1972) 1.85
Familial protein S deficiency is associated with recurrent thrombosis. J Clin Invest (1984) 1.84
Predictors of subclinical nodal involvement in clinical stages I and II non-small cell lung cancer: implications in the inoperable and three-dimensional dose-escalation settings. Int J Radiat Oncol Biol Phys (1999) 1.82
Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res (1996) 1.82
Effects of corticosteroids on human monocyte function. J Clin Invest (1974) 1.81
Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood (1982) 1.79
Cartilage and bone metabolism in rheumatoid arthritis. Differences between rapid and slow progression of disease identified by serum markers of cartilage metabolism. J Clin Invest (1995) 1.77
Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study. N Engl J Med (1989) 1.70
Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. Blood (1981) 1.68
Dissociation by colchicine of the hexose monophosphate shunt activation from the bactericidal activity of the leukocyte. Infect Immun (1971) 1.64
Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer. Am J Med (1995) 1.60
A potential role for hypochlorous acid in granulocyte-mediated tumor cell cytotoxicity. Blood (1980) 1.59
Use of chlorotoxin for targeting of primary brain tumors. Cancer Res (1998) 1.59
Intravenous immunoglobulin therapy in systemic lupus erythematosus-associated thrombocytopenia. Arthritis Rheum (1990) 1.57
Blood volume redistribution during cross-clamping of the descending aorta. Anesth Analg (1994) 1.52
Phase I trial of iodine-131-chimeric B72.3 (human IgG4) in metastatic colorectal cancer. J Nucl Med (1992) 1.49
Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation. Cancer Biother Radiopharm (1999) 1.49
Cadmium-binding component in Escherichia coli during accommodation to low levels of this ion. Appl Environ Microbiol (1981) 1.49
Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: a Piedmont Oncology Association study. J Clin Oncol (1994) 1.48
Radiation therapy for glottic cancer using 6-MV photons. Cancer (1996) 1.48
Effects of hypoxaemia and bradycardia on neonatal cerebral haemodynamics. Arch Dis Child (1991) 1.47
A feasibility study of extended chemotherapy for locally advanced non-small cell lung cancer: a phase II trial of cancer and leukemia group B. Cancer Invest (1994) 1.47
Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice. Cancer (2000) 1.44
Hodgkin disease survivors at increased risk for problems in psychosocial adaptation. The Cancer and Leukemia Group B. Cancer (1992) 1.44
Hyperthermia of pet animal tumours with self-regulating ferromagnetic thermoseeds. Int J Hyperthermia (1990) 1.43
Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol (2002) 1.42
Melphalan and prednisone plus total bone marrow irradiation as initial treatment for multiple myeloma. Int J Radiat Oncol Biol Phys (1988) 1.41
Tumor shrinkage before intracavitary brachytherapy for cancer of the cervix: radiotherapy alone versus concurrent chemoradiotherapy. Cancer J (2000) 1.41
Social support as a buffer to the psychological impact of stressful life events in women with breast cancer. Cancer (2001) 1.41
A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer. Cancer Res (1994) 1.39
Alternated versus syncopated CHOP-PVB: two studies for the treatment of non-Hodgkin's lymphoma by the Southwest Oncology Group. Cancer Invest (1991) 1.39
Expression of human endogenous retrovirus k envelope transcripts in human breast cancer. Clin Cancer Res (2001) 1.38
Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma. J Clin Oncol (2006) 1.37
The nature of the alpha-methyldopa red-cell antibody. N Engl J Med (1967) 1.37
Clinical radioimmunotherapy. Semin Radiat Oncol (2000) 1.36
An oxygen-dependent mechanism of neutrophil-mediated cytotoxicity. Blood (1980) 1.34
Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors. J Clin Oncol (2000) 1.34
Oxidative mechanisms of monocyte-mediated cytotoxicity. Proc Natl Acad Sci U S A (1980) 1.33
Phase I study of phenylacetate administered twice daily to patients with cancer. Cancer (1995) 1.33
Recruitment failure in early neonatal research. Arch Dis Child Fetal Neonatal Ed (2004) 1.31
Characterization of a messenger RNA polynucleotide vaccine vector. Cancer Res (1995) 1.30
Neutron diffraction identifies His 57 as the catalytic base in trypsin. Nature (1980) 1.23
Factors predicting patterns of recurrence after resection of N1 non-small cell lung carcinoma. Ann Thorac Surg (1999) 1.22
Human immune response to monoclonal antibodies. J Immunother Emphasis Tumor Immunol (1994) 1.22
Mode of delivery and survival in babies weighing less than 2000 g at birth. Br Med J (1980) 1.21
Survival advantage of adjuvant chemotherapy in high-risk node-negative breast cancer: ten-year analysis--an intergroup study. J Clin Oncol (1998) 1.21
Human monocyte, lymphocyte, and granulocyte antibody-dependent cell-mediated cytotoxicity toward tumor cells. I. General characteristics of cytolysis. J Immunol (1979) 1.20
A Sindbis virus mRNA polynucleotide vector achieves prolonged and high level heterologous gene expression in vivo. Nucleic Acids Res (1995) 1.20
The effects of ascorbic acid on bactericidal mechanisms of neutrophils. J Infect Dis (1971) 1.19
Augmentation of human natural cell-mediated cytotoxicity by recombinant human interleukin 2. J Immunol (1984) 1.17
Induction of T-cells differentiation in vitro by thymus epithelial cells. Ann N Y Acad Sci (1975) 1.17
Cloning and expression of the growth hormone-dependent insulin-like growth factor-binding protein. Mol Endocrinol (1988) 1.17
Superoxide generation by human monocytes and macrophages. Am J Hematol (1978) 1.16
CD16+ monocytes in patients with cancer: spontaneous elevation and pharmacologic induction by recombinant human macrophage colony-stimulating factor. Blood (1995) 1.16
Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in metastatic adenocarcinoma: comparison of intradermal versus subcutaneous administration. Clin Cancer Res (1999) 1.15
Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers. J Clin Oncol (2000) 1.15
The polyp prevention trial I: rationale, design, recruitment, and baseline participant characteristics. Cancer Epidemiol Biomarkers Prev (1996) 1.15
Permanent Genetic Resources added to Molecular Ecology Resources Database 1 May 2009-31 July 2009. Mol Ecol Resour (2009) 1.15
Mesenteric angiopathy, intestinal gangrene, and midgut carcinoids. Surgery (1981) 1.15